Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 355

1.

How much is Fatigue Explained by Standard Clinical Characteristics of Disease Activity in Patients with Inflammatory Arthritis: A Longitudinal Study.

Minnock P, McKee G, Bresnihan B, FitzGerald O, Veale D.

Arthritis Care Res (Hoboken). 2014 Jun 25. doi: 10.1002/acr.22387. [Epub ahead of print]

PMID:
24966144
[PubMed - as supplied by publisher]
2.

High Prevalence of Metabolic Syndrome and of Insulin Resistance in Psoriatic Arthritis is Associated with the Severity of Underlying Disease.

Haroon M, Gallagher P, Heffernan E, FitzGerald O.

J Rheumatol. 2014 Jul;41(7):1357-65. doi: 10.3899/jrheum.140021. Epub 2014 Jun 15.

PMID:
24931949
[PubMed - in process]
3.

A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool).

Haroon M, O'Rourke M, Ramasamy P, Murphy CC, FitzGerald O.

Ann Rheum Dis. 2014 Jun 13. pii: annrheumdis-2014-205358. doi: 10.1136/annrheumdis-2014-205358. [Epub ahead of print]

PMID:
24928841
[PubMed - as supplied by publisher]
4.

GRAPPA 2013 Annual Meeting, rheumatology updates: psoriatic arthritis (PsA) biomarker project, arthritis mutilans, PsA-peripheral spondyloarthritis epidemiology project.

FitzGerald O, Mease PJ, Helliwell PS, Chandran V.

J Rheumatol. 2014 Jun;41(6):1244-8. doi: 10.3899/jrheum.140181.

PMID:
24882863
[PubMed - in process]
5.

Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response.

Helliwell PS, FitzGerald O, Fransen J.

J Rheumatol. 2014 Jun;41(6):1212-7. doi: 10.3899/jrheum.140172.

PMID:
24882854
[PubMed - in process]
6.

Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting.

de Wit M, Campbell W, FitzGerald O, Gladman DD, Helliwell PS, James J, Lindsay C, MacDonald R, McHugh NJ, Mease PJ, Orbai AM, Palominos P, Parkinson A, Tillett W, Goel N.

J Rheumatol. 2014 Jun;41(6):1206-11. doi: 10.3899/jrheum.140171.

PMID:
24882853
[PubMed - in process]
7.

Spondyloarthropathies: Apremilast: welcome advance in treatment of psoriatic arthritis.

FitzGerald O.

Nat Rev Rheumatol. 2014 Jul;10(7):385-6. doi: 10.1038/nrrheum.2014.77. Epub 2014 May 20. No abstract available.

PMID:
24846499
[PubMed - in process]
8.

Patient involvement in outcome measures for psoriatic arthritis.

Tillett W, Adebajo A, Brooke M, Campbell W, Coates LC, FitzGerald O, Gossec L, Helliwell P, Hewlett S, James J, Minnock P, Reast A, O'Sullivan D, de Wit M, McHugh N.

Curr Rheumatol Rep. 2014 May;16(5):418. doi: 10.1007/s11926-014-0418-7.

PMID:
24623563
[PubMed - in process]
9.

Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.

Haroon M, Gallagher P, Fitzgerald O.

Ann Rheum Dis. 2014 Feb 27. doi: 10.1136/annrheumdis-2013-204858. [Epub ahead of print]

PMID:
24525911
[PubMed - as supplied by publisher]
10.

Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11.

Coates LC, FitzGerald O, Mease PJ, Gladman DD, Strand V, Goel N, Campbell I, Krueger G, McHugh NJ, Helliwell PS.

J Rheumatol. 2014 Apr;41(4):782-91. doi: 10.3899/jrheum.131250. Epub 2014 Feb 1.

PMID:
24488420
[PubMed - in process]
11.

Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools.

Coates LC, Walsh J, Haroon M, Fitzgerald O, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, Cerio R, Chattopadhyay C, Chinoy H, Goodfield MJ, Kay L, Kelly S, Kirkham BW, Lovell CR, Marzo-Ortega H, McHugh N, Murphy R, Reynolds NJ, Smith CH, Stewart EJ, Warren RB, Waxman R, Wilson HE, Helliwell PS.

Arthritis Care Res (Hoboken). 2014 Jan 27. doi: 10.1002/acr.22284. [Epub ahead of print]

PMID:
24470406
[PubMed - as supplied by publisher]
12.

Editorial: emerging evidence for critical involvement of the interleukin-17 pathway in both psoriasis and psoriatic arthritis.

Fitzgerald O, Winchester R.

Arthritis Rheumatol. 2014 May;66(5):1077-80. doi: 10.1002/art.38370. No abstract available.

PMID:
24470140
[PubMed - in process]
13.

Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder.

Balogh E, Madruga Dias J, Orr C, Mullan R, Harty L, FitzGerald O, Gallagher P, Molloy M, O'Flynn E, Kelly A, Minnock P, O'Neill M, Moore L, Murray M, Fearon U, Veale DJ.

Arthritis Res Ther. 2013 Dec 24;15(6):R221. doi: 10.1186/ar4421.

PMID:
24365061
[PubMed - in process]
Free PMC Article
14.

Th17 and Th22 cells in psoriatic arthritis and psoriasis.

Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, Smith M, Thomas R, Gaston H.

Arthritis Res Ther. 2013 Sep 26;15(5):R136. doi: 10.1186/ar4317.

PMID:
24286492
[PubMed - in process]
Free PMC Article
15.

Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis?

Lubrano E, Soriano E, FitzGerald O.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S54-8. Epub 2013 Oct 4. Review.

PMID:
24129139
[PubMed - indexed for MEDLINE]
16.

Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis.

Tang F, Sally B, Ciszewski C, Abadie V, Curran SA, Groh V, Fitzgerald O, Winchester RJ, Jabri B.

PLoS One. 2013 Sep 25;8(9):e76292. doi: 10.1371/journal.pone.0076292. eCollection 2013.

PMID:
24086722
[PubMed - in process]
Free PMC Article
17.

Late onset tuberculosis infection in patients receiving anti-TNF╬▒ therapy.

Mongey AB, Doran JP, Kleinerova J, Fitzgerald O, McDonnell TJ.

QJM. 2014 Jan;107(1):69-71. doi: 10.1093/qjmed/hct174. Epub 2013 Aug 22. No abstract available.

PMID:
23970181
[PubMed - in process]
18.

Tumor necrosis factor inhibition modulates thrombospondin-1 expression in human inflammatory joint disease through altered NR4A2 activity.

McMorrow JP, Crean D, Gogarty M, Smyth A, Connolly M, Cummins E, Veale D, Fearon U, Tak PP, Fitzgerald O, Murphy EP.

Am J Pathol. 2013 Oct;183(4):1243-57. doi: 10.1016/j.ajpath.2013.06.029. Epub 2013 Aug 6.

PMID:
23933487
[PubMed - indexed for MEDLINE]
19.

New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease.

Boehncke WH, Kirby B, Fitzgerald O, van de Kerkhof PC.

J Eur Acad Dermatol Venereol. 2014 Mar;28(3):264-70. doi: 10.1111/jdv.12222. Epub 2013 Aug 1.

PMID:
23909874
[PubMed - in process]
20.

Biomarkers: project update from the GRAPPA 2012 annual meeting.

FitzGerald O, Mease PJ.

J Rheumatol. 2013 Aug;40(8):1453-4. doi: 10.3899/jrheum.130462.

PMID:
23908545
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk